Has Uchenna Orji received payments from drug or device companies?

Yes. Drug and device makers reported $5,996 in general payments to Uchenna Orji across 289 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Uchenna Orji did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Uchenna Orji come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Uchenna Orji

Nurse Practitioner · Moreno Valley, CANPI 1457770836

Payments from drug & device makers

$5,996in general payments, 2019–2025

Across 289 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$1K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$970
AbbVie$588
Alkermes, Inc.$496
Johnson & Johnson$445
Lundbeck LLC$398
plus $2K from 14 others

What the payments were for

Food & beverage$5,94399%
Education$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	52	$1,023
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	53	$970
AbbVie	37	$588
Alkermes, Inc.	20	$496
Johnson & Johnson	10	$445
Lundbeck LLC	20	$398
Neurocrine Biosciences, Inc.	10	$387
Teva Pharmaceuticals USA, Inc.	17	$321
Vanda Pharmaceuticals Inc.	8	$248
Avanir Pharmaceuticals, Inc.	15	$195
Indivior Inc.	8	$174
Sunovion Pharmaceuticals Inc.	12	$166
Supernus Pharmaceuticals, Inc.	6	$135
Corium, LLC	6	$121
Ironshore Pharmaceuticals Inc.	4	$91
E.r. Squibb & Sons, L.L.C.	3	$71
Takeda Pharmaceuticals U.S.A., Inc.	3	$68
Noven Therapeutics, LLC	2	$40
Sage Therapeutics, LLC	1	$29
Almatica Pharma LLC	2	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,996 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TrintellixVortioxetine Hydrobromide	20	$9,360
Duloxetine Hcl	28	$873
Buspirone Hcl	79	$563
Quetiapine Fumarate	44	$540
Hydroxyzine Pamoate	43	$487
Aripiprazole	12	$417
Lurasidone Hcl	14	$372
Sertraline Hcl	47	$351
Trazodone Hcl	52	$312
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	11	$221
Olanzapine	20	$206
Mirtazapine	25	$131
Risperidone	17	$104
Clonazepam	17	$57
Escitalopram Oxalate	18	$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$68	$9,36020 claims
Almatica Pharma LLCSertraline Hcl	$29	$35147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Moreno Valley

Rhonda HewittStanford$917K
Linda TrinhIrvine$899K
Denise SinagaNorthridge$728K
Debbie TaySanta Monica$642K
Joe GorelickCampbell$638K
Lynsey LakinArcadia$540K
Kelly ChoiRancho Cucamonga$483K
Hamta ZareStanford$428K
Shawna ChrismanRoseville$425K
Angelina CollinsSan Diego$356K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →